Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07121244) titled 'A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer' on Aug. 6.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Radionetics Oncology

Condition: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer Metastatic Hormone Receptor Positive Breast Cancer

Intervention: Drug: 68Ga-R11228

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 15, 2025

Target Sample Size: 62

To know more, visit https://clinicaltrials.gov/ct...